Drug Repositioning Service Market Projected to Reach $45.92 Billion by 2030

Dublin, Sept. 16, 2026 /CourierPR/ -- The global drug repositioning service market is poised for significant growth, projected to reach $45.92 billion by 2030, according to a new report from ResearchAndMarkets.com. This market, which saw a value of $34.2 billion in 2025, is expected to grow at a compound annual growth rate (CAGR) of 6.1% over the next five years. The acceleration in growth is driven by the increasing demand for cost-efficient drug development, broader adoption of artificial intelligence (AI) technologies, and a greater emphasis on rare and orphan diseases.

Historically, the market has been supported by rising pharmaceutical research and development costs, the availability of extensive legacy drug data, and the need for shorter drug development cycles. Early adopters of computational drug discovery technologies have been able to identify new therapeutic applications for existing compounds more efficiently. The report highlights that the market is expected to expand further due to the increasing regulatory acceptance of repurposed drugs and the growing use of AI-based drug repurposing platforms.

Key trends in the drug repositioning service market include the growing use of AI to analyze scientific literature, biological information, existing compounds, and clinical data. These technologies are improving the transition from hypothesis generation to experimental validation, helping researchers uncover previously unreported relationships between diseases and potential treatments. For instance, in November 2024, Japan-based UBE and FRONTEO initiated a co-creation project to advance drug repositioning research. The initiative combines data analysis with biological testing to improve collaboration across the discovery and validation process. It also applies FRONTEO's Drug Discovery AI Factory and KIBIT technology to identify new relationships between diseases and molecules.

Strategic acquisitions are also reshaping the competitive landscape. In January 2024, US-based healthcare group Cosmos Health Inc. acquired the Cloudscreen platform from Greece-based Cloudpharm P.C. for an undisclosed amount. The acquisition is intended to support Cosmos Health's drug repurposing initiatives by using Cloudscreen's AI capabilities to identify potential new therapeutic applications for existing medicines more effectively.

Drug repositioning services enable pharmaceutical companies to identify additional uses for existing drugs, strengthen the value of established portfolios, and reduce some of the risks associated with developing entirely new compounds. By applying existing clinical evidence, biological research, and advanced analytics, service providers can help shorten development timelines and lower costs while supporting the delivery of effective treatments. The market includes services for generic medicines and drugs that failed during clinical trials, with key therapeutic areas including oncology, neurology, infectious diseases, and cardiovascular diseases.

North America was the largest regional market for drug repositioning services in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market spans a wide range of countries, including Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

The report identifies several key players in the market, including Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, and BenevolentAI Limited.

The increasing healthcare expenditure is expected to remain a significant driver of market growth. Higher medical costs, continued technological advancement, and rising demand for healthcare services are leading to greater investment in research and clinical development. According to the UK Office for National Statistics, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023.

Artificial intelligence is becoming increasingly important across the drug repositioning service market. Companies are using computational platforms to analyze scientific literature, biological information, existing compounds, and clinical data. These technologies can improve the transition from hypothesis generation to experimental validation while helping researchers uncover previously unreported relationships between diseases and potential treatments.